Researchers from Massachusetts General Hospital (MGH, Boston, USA) have reported the detection and characterisation of thrombosis using fibrin-targeted positron emission tomography and magnetic resonance in a first-in-human study published in JACC: Cardiovascular Imaging.
Atrial fibrillation (AF) can cause clots to form in the heart that may then dislodge and flow to the brain, potentially leading to a stroke. The standard way to detect these clots requires patients to be sedated and to have a transesophageal ultrasound. The investigators tested a targeted contrast agent to detect and image these clots noninvasively. The agent has a strong affinity for fibrin, a component of blood clots, and is detected with a radioactive copper tag.
“The idea behind the technology is that the agent will find and bind to blood clots anywhere in the body—not just in the heart—and make the clots detectable like a bright star in the night sky,” says senior author David Sosnovik, director of the Program in Cardiovascular Imaging within MGH’s Martinos Center for Biomedical Imaging and an associate professor of Medicine at Harvard Medical School (Boston, USA). “In some ways this is analogous to doing a smart search with a search engine such as Google, where the search terms one uses guide the search. We inject the agent into a small peripheral vein and it circulates throughout the human body on its search for clots.”
If no clots are detected, the agent is excreted from the body; however, if it finds a clot and binds to it, clinicians can detect it with an imaging technique known as positron emission tomography, the researchers suggest.
Sosnovik and colleagues examined how the agent reacts (specifically, its metabolism and pharmacokinetics) in eight healthy volunteers. After injection, the agent was initially stable within the body and then was cleared from tissues within several hours, suggesting that it was safe. Next, the team administered the agent to patients with AF, some with clots in the heart and some without. Imaging tests of the heart revealed bright signals within the clots that were not seen in patients without clots.
“Obviously much more work and many more studies will need to be done before this changes routine clinical practice, but this first-in-human study is an important step,” says Sosnovik. “Importantly, this smart or molecularly targeted agent can be used to detect clots anywhere in the body.”
Sosnovik stressed that the multidisciplinary nature of this project was critical to its success, with vital roles played by diverse scientists, including Peter Caravan, who invented and developed the study’s agent and is the co-director of MGH’s Institute for Innovation in Imaging.
“This probe was invented and optimised in my laboratory by a dedicated team of chemists and biologists through the support of the National Heart Lung and Blood Institute of the National Institutes of Health,” says Caravan. “It is extremely gratifying to see these years of effort come to fruition with a fibrin-specific PET probe with the potential to make a real impact on human health.”
